MTOR and melanoma: In another previous in vitro study using melanoma cell lines, a high degree of cross-resistance to a B-RAF inhibitor (vemurafenib) and a MEK inhibitor (AZD6244) was reported, and genetic or pharmacological inhibition of the PI3K/AKT/mTOR pathway was found to partially or completely reverse this resistance [39].